REGULATORY

• Luxturna Priced at 49.6 Million Yen per Vial, Peak Sales Put at 500 Million Yen with 5 Patients
  August 24, 2023

• Hemlibra, Lynparza, Zejula Face Quarterly Re-Pricing, 7.7-10.2% Cut in November
  August 24, 2023

• Japan Approves Enhertu’s NSCLC Use, More Label Expansions
  August 24, 2023

• Novo’s Obesity Med Wegovy Skips Listing Again in August
  August 24, 2023

• Japan Designates Loxoprofen Cold Meds as Behind the Counter Drugs
  August 23, 2023

• Japan Looks to Launch Innovation Tax Incentive to Ramp Up R&D Investments
  August 23, 2023

• Only 4 “G1” LLPs to Make Exit, 62 to Get Generic Prices in 2024 as Withdrawal Scheme Hits Snag
  August 23, 2023

• MHLW Generics Study Group Discusses Yardsticks to Gauge Manufacturers’ Efforts towards Stabilizing Supplies
  August 22, 2023

• Relief Claims OK’ed for 9 More Deaths after COVID Vaccination
  August 22, 2023

• Japan Panel OKs Novartis’ siRNA Dyslipidemia Therapy and More
  August 22, 2023

• Eisai’s Alzheimer’s Drug Clears Advisory Panel, Now in Line for Japan Approval
  August 22, 2023

• New HIV Cases Reported in 2022 Hit 20-Year Low
  August 21, 2023

• MOF Budget Examiner Eager to Reshuffle Resources for Patented Drugs, LLPs
  August 21, 2023

• MEXT Pushes Joint Negotiations for Drug Purchases at University Hospitals
  August 17, 2023

• GSK’s Arexvy, 1st RSV Vaccine, Up for Japan Panel Review on Aug. 28
  August 16, 2023

• Govt to Properly Discuss Public Funding for COVID Drugs after October: Minister
  August 16, 2023

• Japan OKs 1st DPP-4 Generic for Januvia, Zytiga Draws 6 Entrants towards December Listing
  August 16, 2023

• Entries into Generic Business Should Be Regulated by Law: LDP Lawmaker
  August 10, 2023

• Japan Panel OKs Rollout of XBB.1.5-Based COVID Vaccines on Sept. 20
  August 10, 2023

• Japan’s Pandemic Response Agency Officially Set to Launch on September 1
  August 10, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 76
• 77
• 78
• 79
• 80
• 81
• 82
• 83
• 84
• …
• Next ›
• 最終 »